Cinclus Pharma Holding
Cinclus Pharma Holding AB is a Swedish clinical-stage biopharmaceutical company developing novel small molecule therapies for acid-related gastrointestinal conditions. The company's primary drug candidate is linaprazan glurate, a P-CAB designed to treat severe erosive gastroesophageal reflux disease and Helicobacter pylori infections. Principal revenue is currently driven by research milestone payments, collaborative agreements, and development capital raised to advance clinical trials toward commercial authorization. Core end markets encompass gastroenterology medical centers, specialty hospitals, and gastrointestinal prescription patients globally. Cinclus Pharma holds a specialized position in the European biopharmaceutical sector as a developer of next-generation P-CAB acid-blocker therapeutics. The company is headquartered in Stockholm, Sweden, and its shares trade on the Nasdaq Stockholm exchange.
2 of the funds FundTelligence covers report a position in Cinclus Pharma Holding.
- Legal name
- Cinclus Pharma Holding AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 2
Funds holding Cinclus Pharma Holding
- Storebrand Sverige Småbolag Plus — Storebrand · 0.02 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.01 % (full portfolio disclosed, October 2026)